{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:27:05Z","timestamp":1790720825281,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.seizure.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T11:41:25Z","timestamp":1566560485000},"page":"247-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy"],"prefix":"10.1016","volume":"71","author":[{"given":"Alessandro","family":"Orsini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Valetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bonuccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Peroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2019.08.012_bib0005","series-title":"Epileptic syndromes in infancy, childhood and adolescence","article-title":"Progressive myoclonus epilepsies","author":"M. R","year":"2019"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0010","first-page":"3","article-title":"The history of progressive myoclonus epilepsies","volume":"18","author":"Genton","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2019.08.012_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neulet.2017.05.014","article-title":"Recent advances in epilepsy genetics","volume":"667","author":"Orsini","year":"2018","journal-title":"Neurosci Lett"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0020","first-page":"28","article-title":"Unverricht-Lundborg disease","volume":"18","author":"Crespel","year":"2016","journal-title":"Epileptic Disord"},{"issue":"March 3","key":"10.1016\/j.seizure.2019.08.012_bib0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.yebeh.2009.01.001","article-title":"Neuropsychological findings in patients with Unverricht-Lundborg disease","volume":"14","author":"Ferlazzo","year":"2009","journal-title":"Epilepsy Behav"},{"issue":"March 3","key":"10.1016\/j.seizure.2019.08.012_bib0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ng0397-298","article-title":"Unstable insertion in the 5\u2032 flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1","volume":"15","author":"Lafreni\u00e8re","year":"1997","journal-title":"Nat Genet"},{"issue":"February 2","key":"10.1016\/j.seizure.2019.08.012_bib0035","first-page":"342","article-title":"Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1)","volume":"60","author":"Lalioti","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"April 4","key":"10.1016\/j.seizure.2019.08.012_bib0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1528-1167.2007.01422.x","article-title":"Molecular background of EPM1-Unverricht-Lundborg disease","volume":"49","author":"Joensuu","year":"2008","journal-title":"Epilepsia"},{"issue":"November 5","key":"10.1016\/j.seizure.2019.08.012_bib0045","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.47.5.1264","article-title":"Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine","volume":"47","author":"Hurd","year":"1996","journal-title":"Neurology"},{"issue":"December 12","key":"10.1016\/j.seizure.2019.08.012_bib0050","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/jnen\/61.12.1085","article-title":"Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease","volume":"61","author":"Shannon","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"January 1","key":"10.1016\/j.seizure.2019.08.012_bib0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mds.21812","article-title":"The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases","volume":"23","author":"Chew","year":"2008","journal-title":"Mov Disord"},{"issue":"Pt A","key":"10.1016\/j.seizure.2019.08.012_bib0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yebeh.2017.02.025","article-title":"DSM-5 criteria for PTSD in parents of pediatric patients with epilepsy: what are the changes with respect to DSM-IV-TR?","volume":"70","author":"Carmassi","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"October (Pt 5)","key":"10.1016\/j.seizure.2019.08.012_bib0065","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/brain\/112.5.1261","article-title":"Myoclonus epilepsy and ragged-red fibres (MERRF). 2. Electrophysiological studies and comparison with other progressive myoclonus epilepsies","volume":"112","author":"So","year":"1989","journal-title":"Brain"},{"issue":"July\u2013September 3","key":"10.1016\/j.seizure.2019.08.012_bib0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0370-4475(74)80052-3","article-title":"[Electroencephalographic study of myoclonic cerebellar dyssynergia with epilepsy (Ramsay-Hunt syndrome)]","volume":"4","author":"Tassinari","year":"1974","journal-title":"Rev Electroencephalogr Neurophysiol Clin"},{"issue":"May 5","key":"10.1016\/j.seizure.2019.08.012_bib0075","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1528-1167.2006.00553.x","article-title":"Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients","volume":"47","author":"Magaudda","year":"2006","journal-title":"Epilepsia"},{"issue":"March 3","key":"10.1016\/j.seizure.2019.08.012_bib0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.410030309","article-title":"The cherry-red spot--myoclonus syndrome","volume":"3","author":"Rapin","year":"1978","journal-title":"Ann Neurol"},{"issue":"December 24","key":"10.1016\/j.seizure.2019.08.012_bib0085","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1101\/gad.10.24.3156","article-title":"Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis","volume":"10","author":"Bonten","year":"1996","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.seizure.2019.08.012_bib0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/21678707.2015.1025746","article-title":"Pathogenesis, emerging therapeutic targets and treatment in Sialidosis","volume":"3","author":"d\u2019Azzo","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"issue":"June1\u20133","key":"10.1016\/j.seizure.2019.08.012_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-5793(02)02748-5","article-title":"Identification of a CTL4\/Neu1 fusion transcript in a sialidosis patient","volume":"521","author":"Uhl","year":"2002","journal-title":"FEBS Lett"},{"issue":"January 1","key":"10.1016\/j.seizure.2019.08.012_bib0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/humu.10278","article-title":"Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression","volume":"23","author":"Pattison","year":"2004","journal-title":"Hum Mutat"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0105","first-page":"89","article-title":"Sialidoses","volume":"18","author":"Franceschetti","year":"2016","journal-title":"Epileptic Disord"},{"issue":"September 3","key":"10.1016\/j.seizure.2019.08.012_bib0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","article-title":"Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses","volume":"6","author":"Mole","year":"2005","journal-title":"Neurogenetics"},{"issue":"November 11","key":"10.1016\/j.seizure.2019.08.012_bib0115","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","article-title":"NCL diseases - clinical perspectives","volume":"1832","author":"Schulz","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0120","first-page":"73","article-title":"Neuronal ceroid lipofuscinoses","volume":"18","author":"Nita","year":"2016","journal-title":"Epileptic Disord"},{"issue":"2","key":"10.1016\/j.seizure.2019.08.012_bib0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0387-7604(88)80075-5","article-title":"Neuronal ceroid-lipofuscinoses in childhood","volume":"10","author":"Santavuori","year":"1988","journal-title":"Brain Dev"},{"issue":"October 10","key":"10.1016\/j.seizure.2019.08.012_bib0130","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.bbadis.2006.06.010","article-title":"The neuronal ceroid-lipofuscinoses: from past to present","volume":"1762","author":"Haltia","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"April 4","key":"10.1016\/j.seizure.2019.08.012_bib0135","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbamcr.2008.11.004","article-title":"Neuronal ceroid lipofuscinoses","volume":"1793","author":"Jalanko","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0140","first-page":"103","article-title":"Progressive myoclonus epilepsy associated with neuroserpin inclusion bodies (neuroserpinosis)","volume":"18","author":"Roussel","year":"2016","journal-title":"Epileptic Disord"},{"issue":"November 24","key":"10.1016\/j.seizure.2019.08.012_bib0145","doi-asserted-by":"crossref","first-page":"14118","DOI":"10.1073\/pnas.96.24.14118","article-title":"Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene","volume":"96","author":"Seeds","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"October","key":"10.1016\/j.seizure.2019.08.012_bib0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2377-7-37","article-title":"Neuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women study","volume":"7","author":"Cole","year":"2007","journal-title":"BMC Neurol"},{"issue":"February 6411","key":"10.1016\/j.seizure.2019.08.012_bib0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/361453a0","article-title":"Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation","volume":"361","author":"Qian","year":"1993","journal-title":"Nature"},{"issue":"May 19","key":"10.1016\/j.seizure.2019.08.012_bib0160","doi-asserted-by":"crossref","first-page":"17367","DOI":"10.1074\/jbc.M200680200","article-title":"Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro","volume":"277","author":"Belorgey","year":"2002","journal-title":"J Biol Chem"},{"issue":"August 16","key":"10.1016\/j.seizure.2019.08.012_bib0165","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1111\/j.1432-1033.2004.04270.x","article-title":"Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB","volume":"271","author":"Belorgey","year":"2004","journal-title":"Eur J Biochem"},{"issue":"September 6751","key":"10.1016\/j.seizure.2019.08.012_bib0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/43894","article-title":"Familial dementia caused by polymerization of mutant neuroserpin","volume":"401","author":"Davis","year":"1999","journal-title":"Nature"},{"issue":"July 1","key":"10.1016\/j.seizure.2019.08.012_bib0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/01.wnl.0000265052.99144.b5","article-title":"Clinical and neuropathologic study of a French family with a mutation in the neuroserpin gene","volume":"69","author":"Gourfinkel-An","year":"2007","journal-title":"Neurology"},{"issue":"September 5","key":"10.1016\/j.seizure.2019.08.012_bib0180","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1750-3639.2011.00481.x","article-title":"Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 gene","volume":"21","author":"Hagen","year":"2011","journal-title":"Brain Pathol"},{"issue":"July 1","key":"10.1016\/j.seizure.2019.08.012_bib0185","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2012.05.001","article-title":"Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1","volume":"91","author":"Zhou","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"December 6","key":"10.1016\/j.seizure.2019.08.012_bib0190","first-page":"314","article-title":"Spinal muscular atrophy with progressive myoclonic epilepsy: report of new cases and review of the literature","volume":"33","author":"Haliloglu","year":"2002","journal-title":"Neuropediatrics"},{"issue":"September 3","key":"10.1016\/j.seizure.2019.08.012_bib0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410060309","article-title":"Hereditary myoclonus and progressive distal muscular atrophy","volume":"6","author":"Jankovic","year":"1979","journal-title":"Ann Neurol"},{"issue":"May 5","key":"10.1016\/j.seizure.2019.08.012_bib0200","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/epi.12977","article-title":"Spinal muscular atrophy associated with progressive myoclonic epilepsy: a rare condition caused by mutations in ASAH1","volume":"56","author":"Rubboli","year":"2015","journal-title":"Epilepsia"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0205","first-page":"128","article-title":"Spinal muscular atrophy associated with progressive myoclonus epilepsy","volume":"18","author":"Topaloglu","year":"2016","journal-title":"Epileptic Disord"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0210","first-page":"135","article-title":"Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations","volume":"18","author":"Nascimento","year":"2016","journal-title":"Epileptic Disord"},{"issue":"January 1","key":"10.1016\/j.seizure.2019.08.012_bib0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ng.3144","article-title":"A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy","volume":"47","author":"Muona","year":"2015","journal-title":"Nat Genet"},{"issue":"February 2","key":"10.1016\/j.seizure.2019.08.012_bib0220","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/geno.1993.1075","article-title":"Localization of a highly conserved human potassium channel gene (NGK2-KV4; KCNC1) to chromosome 11p15","volume":"15","author":"Ried","year":"1993","journal-title":"Genomics"},{"issue":"November 5","key":"10.1016\/j.seizure.2019.08.012_bib0225","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1152\/jn.1999.82.5.2476","article-title":"Function of specific K(+) channels in sustained high-frequency firing of fast-spiking neocortical interneurons","volume":"82","author":"Erisir","year":"1999","journal-title":"J Neurophysiol"},{"issue":"September 9","key":"10.1016\/j.seizure.2019.08.012_bib0230","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0166-2236(00)01892-0","article-title":"Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing","volume":"24","author":"Rudy","year":"2001","journal-title":"Trends Neurosci"},{"issue":"May 10","key":"10.1016\/j.seizure.2019.08.012_bib0235","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1523\/JNEUROSCI.17-10-03425.1997","article-title":"Control of neurotransmitter release by presynaptic waveform at the granule cell to Purkinje cell synapse","volume":"17","author":"Sabatini","year":"1997","journal-title":"J Neurosci"},{"issue":"January 1","key":"10.1016\/j.seizure.2019.08.012_bib0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1113\/jphysiol.2013.264309","article-title":"Kv3.3 channels harbouring a mutation of spinocerebellar ataxia type 13 alter excitability and induce cell death in cultured cerebellar Purkinje cells","volume":"592","author":"Irie","year":"2014","journal-title":"J Physiol"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0245","first-page":"63","article-title":"SCARB2\/LIMP2 deficiency in action myoclonus-renal failure syndrome","volume":"18","author":"Dibbens","year":"2016","journal-title":"Epileptic Disord"},{"issue":"November 4","key":"10.1016\/j.seizure.2019.08.012_bib0250","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"issue":"July 14","key":"10.1016\/j.seizure.2019.08.012_bib0255","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1093\/hmg\/ddn124","article-title":"A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome","volume":"17","author":"Balreira","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"August 9","key":"10.1016\/j.seizure.2019.08.012_bib0260","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mds.25083","article-title":"A case of severe hearing loss in action myoclonus renal failure syndrome resulting from mutation in SCARB2","volume":"27","author":"Perandones","year":"2012","journal-title":"Mov Disord"},{"issue":"October Pt 10","key":"10.1016\/j.seizure.2019.08.012_bib0265","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/brain\/awh263","article-title":"Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder","volume":"127","author":"Badhwar","year":"2004","journal-title":"Brain"},{"issue":"June 6","key":"10.1016\/j.seizure.2019.08.012_bib0270","first-page":"812","article-title":"Mutation of SCARB2 in a patient with progressive myoclonus epilepsy and demyelinating peripheral neuropathy","volume":"68","author":"Dibbens","year":"2011","journal-title":"Arch Neurol"},{"issue":"August 5","key":"10.1016\/j.seizure.2019.08.012_bib0275","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/nan.12057","article-title":"Progressive myoclonus epilepsy: extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations","volume":"40","author":"Fu","year":"2014","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"December 12","key":"10.1016\/j.seizure.2019.08.012_bib0280","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/j.1528-1167.2011.03307.x","article-title":"Clinical and neurophysiologic features of progressive myoclonus epilepsy without renal failure caused by SCARB2 mutations","volume":"52","author":"Rubboli","year":"2011","journal-title":"Epilepsia"},{"issue":"October 4","key":"10.1016\/j.seizure.2019.08.012_bib0285","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.21765","article-title":"SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure","volume":"66","author":"Dibbens","year":"2009","journal-title":"Ann Neurol"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0290","first-page":"94","article-title":"Myoclonus epilepsy in mitochondrial disorders","volume":"18","author":"Lamperti","year":"2016","journal-title":"Epileptic Disord"},{"issue":"December 6","key":"10.1016\/j.seizure.2019.08.012_bib0295","first-page":"1179","article-title":"Mitochondrial genetics: principles and practice","volume":"51","author":"Shoffner","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"June 6","key":"10.1016\/j.seizure.2019.08.012_bib0300","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1528-1167.2008.01877.x","article-title":"Status epilepticus in children with Alpers\u2019 disease caused by POLG1 mutations: EEG and MRI features","volume":"50","author":"Wolf","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.08.012_bib0305","series-title":"Dyssynergia cerebellaris myoclonica-primary atrophy of the dentate system: a contribution to the pathology and symptomatology of the cerebellum","author":"Hunt","year":"1922"},{"issue":"September 9437","key":"10.1016\/j.seizure.2019.08.012_bib0310","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(04)16983-3","article-title":"Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study","volume":"364","author":"Luoma","year":"2004","journal-title":"Lancet"},{"issue":"May 5","key":"10.1016\/j.seizure.2019.08.012_bib0315","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ajhg.2011.04.011","article-title":"A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia","volume":"88","author":"Corbett","year":"2011","journal-title":"Am J Hum Genet"},{"issue":"April Pt 4","key":"10.1016\/j.seizure.2019.08.012_bib0320","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/brain\/awt021","article-title":"North Sea\u2019 progressive myoclonus epilepsy: phenotype of subjects with GOSR2 mutation","volume":"136","author":"Boiss\u00e9 Lomax","year":"2013","journal-title":"Brain"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0325","first-page":"111","article-title":"GOSR2: a progressive myoclonus epilepsy gene","volume":"18","author":"Dibbens","year":"2016","journal-title":"Epileptic Disord"},{"issue":"August 1","key":"10.1016\/j.seizure.2019.08.012_bib0330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12035-011-8194-0","article-title":"Progressive myoclonic epilepsy-associated gene KCTD7 is a regulator of potassium conductance in neurons","volume":"44","author":"Azizieh","year":"2011","journal-title":"Mol Neurobiol"},{"issue":"June 6","key":"10.1016\/j.seizure.2019.08.012_bib0335","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ana.21121","article-title":"Mutation of a potassium channel-related gene in progressive myoclonic epilepsy","volume":"61","author":"Van Bogaert","year":"2007","journal-title":"Ann Neurol"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0340","first-page":"115","article-title":"KCTD7-related progressive myoclonus epilepsy","volume":"18","author":"Van Bogaert","year":"2016","journal-title":"Epileptic Disord"},{"issue":"April 4","key":"10.1016\/j.seizure.2019.08.012_bib0345","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"issue":"July 1","key":"10.1016\/j.seizure.2019.08.012_bib0350","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0887-8994(00)00276-9","article-title":"Lafora\u2019s disease: towards a clinical, pathologic, and molecular synthesis","volume":"25","author":"Minassian","year":"2001","journal-title":"Pediatr Neurol"},{"issue":"February 2","key":"10.1016\/j.seizure.2019.08.012_bib0355","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ncpneuro0706","article-title":"Typical progression of myoclonic epilepsy of the Lafora type: a case report","volume":"4","author":"Striano","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"October 2","key":"10.1016\/j.seizure.2019.08.012_bib0360","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet"},{"issue":"September Pt 9","key":"10.1016\/j.seizure.2019.08.012_bib0365","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1093\/brain\/aws205","article-title":"Early-onset lafora body disease","volume":"135","author":"Turnbull","year":"2012","journal-title":"Brain"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0370","first-page":"38","article-title":"Lafora disease","volume":"18","author":"Turnbull","year":"2016","journal-title":"Epileptic Disord"},{"issue":"April 4","key":"10.1016\/j.seizure.2019.08.012_bib0375","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1528-1167.2009.02498.x","article-title":"Posterior glucose hypometabolism in Lafora disease: early and late FDG-PET assessment","volume":"51","author":"Jennesson","year":"2010","journal-title":"Epilepsia"},{"issue":"June 2","key":"10.1016\/j.seizure.2019.08.012_bib0380","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/brain\/103.2.315","volume":"103","author":"Robitaille","year":"1980","journal-title":"Brain"},{"issue":"January","key":"10.1016\/j.seizure.2019.08.012_bib0385","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-6606-7-7","article-title":"Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease","volume":"7","author":"Ortolano","year":"2014","journal-title":"Mol Brain"},{"issue":"March 3","key":"10.1016\/j.seizure.2019.08.012_bib0390","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cmet.2011.01.017","article-title":"Phosphate incorporation during glycogen synthesis and Lafora disease","volume":"13","author":"Tagliabracci","year":"2011","journal-title":"Cell Metab"},{"issue":"August 8","key":"10.1016\/j.seizure.2019.08.012_bib0395","article-title":"Pathogenesis of lafora disease: transition of soluble glycogen to insoluble polyglucosan","volume":"18","author":"Sullivan","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"September S2","key":"10.1016\/j.seizure.2019.08.012_bib0400","first-page":"145","article-title":"Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials","volume":"18","author":"Michelucci","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2019.08.012_bib0405","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebcr.2014.09.003","article-title":"Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel","volume":"2","author":"Dirani","year":"2014","journal-title":"Epilepsy Behav Case Rep"},{"issue":"August 8","key":"10.1016\/j.seizure.2019.08.012_bib0410","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1528-1157.2000.tb00293.x","article-title":"Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type","volume":"41","author":"Smith","year":"2000","journal-title":"Epilepsia"},{"issue":"March 3","key":"10.1016\/j.seizure.2019.08.012_bib0415","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1167.2010.02884.x","article-title":"Chronic high-frequency deep-brain stimulation in progressive myoclonic epilepsy in adulthood--report of five cases","volume":"52","author":"Wille","year":"2011","journal-title":"Epilepsia"},{"issue":"May 2","key":"10.1016\/j.seizure.2019.08.012_bib0420","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eplepsyres.2006.01.007","article-title":"A pilot study of a ketogenic diet in patients with Lafora body disease","volume":"69","author":"Cardinali","year":"2006","journal-title":"Epilepsy Res"},{"issue":"September 9","key":"10.1016\/j.seizure.2019.08.012_bib0425","article-title":"Correction of a splicing mutation affecting an unverricht-lundborg disease patient by antisense therapy","volume":"9","author":"Matos","year":"2018","journal-title":"Genes (Basel)"},{"issue":"4","key":"10.1016\/j.seizure.2019.08.012_bib0430","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/epi.13662","article-title":"Perampanel in 12 patients with Unverricht-Lundborg disease","volume":"58","author":"Crespel","year":"2017","journal-title":"Epilepsia"},{"issue":"July 3","key":"10.1016\/j.seizure.2019.08.012_bib0435","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2005.03.007","article-title":"Short-term, high dose enzyme replacement therapy in sialidosis mice","volume":"85","author":"Wang","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"May 5","key":"10.1016\/j.seizure.2019.08.012_bib0440","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"20","key":"10.1016\/j.seizure.2019.08.012_bib0445","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of Intraventricular Cerliponase Alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seizure.2019.08.012_bib0450","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13023-018-0845-z","article-title":"Acid ceramidase deficiency: farber disease and SMA-PME","volume":"13","author":"Yu","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.seizure.2019.08.012_bib0455","doi-asserted-by":"crossref","first-page":"06","DOI":"10.3390\/ijms19071825","article-title":"The bacterial protein CNF1 as a potential therapeutic strategy against mitochondrial diseases: a pilot study","volume":"19","author":"Fabbri","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.seizure.2019.08.012_bib0460","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ymgme.2014.12.029","article-title":"Clinical characteristics of type III Gaucher disease in children and adolescents enrolled in a trial of velaglucerase alfa","volume":"114","author":"Dridi","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"March 3","key":"10.1016\/j.seizure.2019.08.012_bib0465","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119304625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119304625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:55:41Z","timestamp":1761011741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131119304625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":93,"alternative-id":["S1059131119304625"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.08.012","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}